Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
WAT Stock Forecast 2026-2027
$376.39
Current Price
$36.96B
Market Cap
Buy 16
Hold 9
Sell 0
Wall St Analyst Ratings
Distance to WAT Price Targets
+22.2%
To High Target of $460.00
+9.6%
To Median Target of $412.50
-7.3%
To Low Target of $349.00
WAT Price Momentum
+2.2%
1 Week Change
+5.2%
1 Month Change
+30.0%
1 Year Change
-0.9%
Year-to-Date Change
-9.1%
From 52W High of $414.15
+36.8%
From 52W Low of $275.05
📊 TOP ANALYST CALLS
Did WAT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Waters is one of their latest high-conviction picks.
Latest WAT Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, WAT has a bullish consensus with a median price target of $412.50 (ranging from $349.00 to $460.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $376.39, the median forecast implies a 9.6% upside. This outlook is supported by 16 Buy, 9 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
WAT Analyst Ratings
16
Buy
9
Hold
0
Sell
WAT Price Target Range
Low
$349.00
Average
$412.50
High
$460.00
Current: $376.39
Latest WAT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for WAT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 9, 2026 | Morgan Stanley | Kallum Titchmarsh | Equal-Weight | Maintains | $390.00 |
| Jul 9, 2026 | RBC Capital | Dan Leonard | Outperform | Initiates | $435.00 |
| Jul 8, 2026 | Guggenheim | Subbu Nambi | Buy | Reiterates | $440.00 |
| Jul 6, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $410.00 |
| Jun 26, 2026 | Bernstein | Eve Burstein | Outperform | Reinstates | $435.00 |
| Jun 11, 2026 | Piper Sandler | Neutral | Initiates | $N/A | |
| Jun 3, 2026 | HSBC | Buy | Maintains | $N/A | |
| Jun 2, 2026 | B of A Securities | Neutral | Maintains | $N/A | |
| Jun 2, 2026 | Wolfe Research | Mike Polark | Outperform | Assumes | $425.00 |
| May 14, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| May 7, 2026 | Barclays | Overweight | Maintains | $N/A | |
| May 6, 2026 | UBS | Neutral | Maintains | $N/A | |
| May 6, 2026 | JP Morgan | Neutral | Maintains | $N/A | |
| May 6, 2026 | TD Cowen | Hold | Maintains | $N/A | |
| Apr 13, 2026 | UBS | Neutral | Maintains | $N/A | |
| Mar 25, 2026 | Deutsche Bank | Hold | Maintains | $N/A | |
| Feb 23, 2026 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Feb 11, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Feb 11, 2026 | Barclays | Luke Sergott | Overweight | Reinstates | $400.00 |
| Feb 10, 2026 | UBS | Neutral | Maintains | $N/A |
Waters Corporation (WAT) Competitors
The following stocks are similar to Waters based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Waters Corporation (WAT) Financial Data
Waters Corporation has a market capitalization of $36.96B with a P/E ratio of 47.4x. The company generates $3.77B in trailing twelve-month revenue with a 11.9% profit margin.
Revenue growth is +91.4% quarter-over-quarter, while maintaining an operating margin of +2.8% and return on equity of +5.2%.
Valuation Metrics
Market Cap
$36.96B
Enterprise Value
$41.78B
P/E Ratio
47.4x
PEG Ratio
-0.3x
Price/Sales
9.7x
Growth & Margins
Revenue Growth (YoY)
+91.4%
Gross Margin
+46.4%
Operating Margin
+2.8%
Net Margin
+11.9%
EPS Growth
+91.5%
Financial Health
Cash/Price Ratio
+1.3%
Current Ratio
1.8x
Debt/Equity
36.6x
ROE
+5.2%
ROA
+3.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Waters Corporation (WAT) Business Model
About Waters Corporation
What They Do
Provides analytical workflow solutions for various sectors.
Business Model
The company generates revenue by offering a range of scientific instrumentation, including liquid chromatography systems and mass spectrometry platforms, along with related consumables and services. Its business model focuses on delivering integrated instruments and software that support critical applications in drug development, quality control, and environmental testing, catering to a diverse clientele across life sciences, industrial, and academic sectors.
Additional Information
Founded in 1958 and headquartered in Milford, Massachusetts, the company has established a strong global presence, particularly in diagnostics and research workflows. It serves a variety of customers, including biopharmaceutical companies and academic laboratories, emphasizing regulatory compliance and data-driven decision-making in its operations.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
16,000
CEO
Dr. Udit Batra Ph.D.
Country
United States
IPO Year
1995
Website
www.waters.comWaters Corporation (WAT) Latest News & Analysis
Latest News
Quick Summary
Waters Corporation (NYSE: WAT) will announce its Q2 2026 financial results during a conference call on August 4, 2026, at 8:00 a.m.
Why It Matters
The upcoming Q2 2026 results call could reveal key financial performance indicators for Waters Corporation, influencing stock price and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IMU Biosciences and Waters Corporation have formed a strategic partnership to advance IMU’s AI-powered HD Immunology platform, leveraging Waters' flow cytometry and single-cell technologies.
Why It Matters
The partnership enhances IMU Biosciences' capabilities, potentially leading to innovative treatments and increased market value, which could positively impact investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Advancements in GLP-1, insulin, and LNP drug testing enhance biopharmaceutical development, doubling resolving power and sensitivity, and improving regulatory preparedness by reducing production delays.
Why It Matters
Faster drug testing enhances biopharmaceutical development, reducing costs and time to market, which can lead to higher revenues and improved competitive positioning for companies in the sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
A new experimental design integrates heat flow, gas analysis, and electrochemistry to provide early insights into thermal runaway, reducing sample prep time by over 90%.
Why It Matters
The new experimental integration improves efficiency in identifying thermal runaway risks, potentially enhancing safety and reliability in battery technology, influencing investment in related sectors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Waters Corporation (WAT) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for potential stock movements.
Why It Matters
Earnings reports influence stock performance; the upcoming analysis will guide investor sentiment and potential price movements for Waters (WAT).
Source: Zacks Investment Research
Market Sentiment:
Positive
Waters Corporation (WAT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
1 month ago
Quick Summary
Waters Corporation (WAT) presented at the Jefferies Global Healthcare Conference 2026, providing insights into their business and strategic direction.
Why It Matters
Waters Corporation's presentation at a major healthcare conference signals its strategic direction and potential growth, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About WAT Stock
What is Waters Corporation's (WAT) stock forecast for 2027?
Based on our analysis of 8 Wall Street analysts, Waters Corporation (WAT) has a median price target of $412.50. The highest price target is $460.00 and the lowest is $349.00.
Is WAT stock a good investment in 2027?
According to current analyst ratings, WAT has 16 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $376.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for WAT stock?
Wall Street analysts predict WAT stock could reach $412.50 in the next 12 months. This represents a 9.6% increase from the current price of $376.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Waters Corporation's business model?
The company generates revenue by offering a range of scientific instrumentation, including liquid chromatography systems and mass spectrometry platforms, along with related consumables and services. Its business model focuses on delivering integrated instruments and software that support critical applications in drug development, quality control, and environmental testing, catering to a diverse clientele across life sciences, industrial, and academic sectors.
What is the highest forecasted price for WAT Waters Corporation?
The highest price target for WAT is $460.00 from at , which represents a 22.2% increase from the current price of $376.39.
What is the lowest forecasted price for WAT Waters Corporation?
The lowest price target for WAT is $349.00 from at , which represents a -7.3% decrease from the current price of $376.39.
What is the overall WAT consensus from analysts for Waters Corporation?
The overall analyst consensus for WAT is bullish. Out of 8 Wall Street analysts, 16 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $412.50.
How accurate are WAT stock price projections?
Stock price projections, including those for Waters Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 15, 2026 6:56 PM UTC